Shares of OneSource Specialty Pharma Limited jumped over 3% after the company announced a strategic partnership with Sweden-based biotechnology firm Xbrane Biopharma AB (Nasdaq: XBRANE). As of 9:22 AM, the shares were trading 2.64% higher at Rs 2,078.70.
The partnership focuses on the commercial manufacturing of Xbrane’s biosimilar portfolio. These biosimilars target reference products with a combined estimated annual peak sales of EUR 23 billion. Notably, Xbrane’s lead product, Ximluci—a biosimilar to ranibizumab—has already secured market authorization in Europe and is currently under review in the U.S.
As part of the agreement, Xbrane will transfer select biosimilar products to OneSource’s state-of-the-art Drug Substance and Drug Product manufacturing facility in Bangalore, India. This move strengthens Xbrane’s global supply chain while enabling OneSource to advance its regulatory capabilities with major agencies like the U.S. FDA and EMA.
Demonstrating deeper alignment, OneSource has also participated in Xbrane’s recent funding round, signalling a long-term commitment between the two companies.
This collaboration positions OneSource as a key player in the global biologics CDMO (Contract Development and Manufacturing Organization) space, while enhancing its visibility in regulated international markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash